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Effects of SlowMo, a Blended Digital Therapy Targeting Reasoning,
on Paranoia Among People With Psychosis
A Randomized Clinical Trial
Philippa Garety, PhD; Thomas Ward, PhD; Richard Emsley, PhD; Kathryn Greenwood, PhD; Daniel Freeman, PhD; David Fowler, MSc;
Elizabeth Kuipers, PhD; Paul Bebbington, PhD; Mar Rus-Calafell, PhD; Alison McGourty, DPsych; Catarina Sacadura, PsyD;
Nicola Collett, DClinPsy; Kirsty James, MSc; Amy Hardy, PhD
IMPORTANCE Persistent paranoia is common among patients with psychosis.
Cognitive-behavioral therapy for psychosis can be effective. However, challenges
in engagement and effectiveness remain.
OBJECTIVE To investigate the effects on paranoia and mechanisms of action of SlowMo,
a digitally supported reasoning intervention, plus usual care compared with usual care only.
DESIGN, SETTING, AND PARTICIPANTS This parallel-arm, assessor-blinded, randomized clinical
trial recruited participants at UK community health services from May 1, 2017,
to May 14, 2019. Eligible participants consisted of a referral sample with
schizophrenia-spectrum psychosis and distressing, persistent (3 months) paranoia.
INTERVENTIONS Individuals were randomized 1:1 to SlowMo, consisting of 8 digitally
supported face-to-face sessions and a mobile app, plus usual care (n = 181) and usual care
only (n = 181).
MAIN OUTCOMES AND MEASURES The primary outcome was paranoia, measured by
the Green et al Paranoid Thoughts Scale (GPTS) total score at 24 weeks. Secondary outcomes
included GPTS total score at 12 weeks and GPTS Part A (reference) and Part B (persecutory)
scores, the Psychotic Symptom Rating Scales (PSYRATS Delusion subscale), reasoning
(belief flexibility, possibility of being mistaken [Maudsley Assessment of Delusions,
rated 0%-100%]), and jumping to conclusions (Beads Task).
RESULTS A total of 361 participants were included in intention-to-treat analysis, of whom 252
(69.8%) were male and 249 (69.0%) were White; the mean (SD) age was 42.6 (11.6) years.
At 24 weeks, 332 participants (92.0%) provided primary outcome data. Of 181 participants in
the SlowMo group, 145 (80.1%) completed therapy. SlowMo plus usual care was not
associated with greater reductions than usual care in GPTS total score at 24 weeks (Cohen d,
0.20; 95% CI, −0.02 to 0.40; P = .06). There were significant effects on secondary paranoia
outcomes at 12 weeks, including GPTS total score (Cohen d, 0.30; 95% CI, 0.09-0.51;
P = .005), Part A score (Cohen d, 0.22; 95% CI, 0.06-0.39; P = .009), and Part B score
(Cohen d, 0.32; 95% CI, 0.08-0.56; P = .009), and at 24 weeks, including Part B score
(Cohen d, 0.25; 95% CI, 0.01-0.49; P = .04) but not Part A score (Cohen d, 0.12; 95% CI,
−0.05 to 0.28; P = .18). Improvements were observed in an observer-rated measure of
persecutory delusions (PSYRATS delusion) at 12 weeks (Cohen d, 0.47; 95% CI, 0.17-0.78;
P = .002) and 24 weeks (Cohen d, 0.50; 95% CI, 0.20-0.80; P = .001) and belief flexibility at
12 weeks (Cohen d, 0.29; 95% CI, 0.09-0.49; P = .004) and 24 weeks (Cohen d, 0.28;
95% CI, 0.08-0.49; P = .005). There were no significant effects on jumping to conclusions.
Improved belief flexibility and worry mediated paranoia change (range mediated, 36%-56%).
CONCLUSIONS AND RELEVANCE SlowMo did not demonstrate significant improvements in the
primary measure of paranoia at 24 weeks; however, a beneficial effect of SlowMo on paranoia
was indicated by the results on the primary measure at an earlier point and on observer-rated
paranoia and self-reported persecution at 12 and 24 weeks. Further work to optimize
SlowMo’s effects is warranted.
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P aranoia, or fear of deliberate harm from others, is amongthe most common symptoms of schizophrenia spec-trum disorders and is associated with substantial dis-
tress and disruption.1 Developing effective interventions for
paranoia is a clinical priority. Meta-analyses of first-
generation cognitive-behavioral therapy for psychosis (CBTp)
have indicated associations with delusions2 and broader posi-
tive symptoms.3 However, marked challenges to treatment en-
gagement, adherence, and effectiveness remain.1,4
SlowMo therapy adopts an interventionist-causal
approach5 to increasing CBTp effectiveness by targeting rea-
soning processes considered causal in paranoia.6 These bi-
ased processes include jumping to conclusions (JTC) (ie, form-
ing rapid judgments using limited information) and belief
inflexibility (reduced metacognitive capacity for reflecting on
and reviewing one’s beliefs and considering alternatives).6-8
SlowMo aims to build awareness of a tendency to JTC and de-
velop increased belief flexibility. SlowMo is the end point of a
decade of development, during which preliminary evidence
that the intervention reduced paranoia severity, mediated by
increased belief flexibility, was found.9-12 Over time, the in-
tervention has focused increasingly on belief flexibility, adopt-
ing the terms fast and slow thinking to communicate reason-
ing concepts.8,13,14 SlowMo also uses digital technology and
inclusive, human-centered design to improve the user expe-
rience with the aim of enhancing engagement and adherence
for the widest possible range of people.14-16 SlowMo builds on
the encouraging findings for stand-alone and blended mobile
phone apps for psychosis17-20 and, to our knowledge, is the first
blended digital psychological intervention for paranoia (using
digitally supported face-to-face therapy and a mobile app).
This randomized clinical trial aimed to test the efficacy of
SlowMo in reducing paranoia and improving reasoning.
We hypothesized that SlowMo would improve paranoia and
reasoning together with outcomes prioritized by the trial’s
service-user consultants: self-concept, quality of life, and well-
being. We also hypothesized that the treatment effects on para-
noia would be mediated through reasoning, specifically be-
lief flexibility and JTC. We also examined worry as an outcome
and mediator because worry mediates change in paranoia.21
However, because worry was not directly targeted by the
treatment, we hypothesized that worry would not mediate
the treatment effects of SlowMo on paranoia.
Methods
Research Design
This parallel-group randomized clinical trial (ISRCTN32448671)
used 1:1 allocation and blinded assessors to test the efficacy
of adding SlowMo therapy to treatment as usual (TAU) to
reduce paranoia severity compared with TAU alone (trial
protocol given in Supplement 1). The trial was performed
from May 1, 2017, to October 31, 2019. Recruitment was from
UK community mental health services across 3 main sites.
The trial received ethical approval from the Camberwell
St Giles research ethics committee, and all participants
gave written informed consent. This study followed the
Consolidated Standards of Reporting Trials (CONSORT)
reporting guideline.22
Participants
Eligible participants met the following criteria: 18 years or older;
persistent (≥3 months) distressing paranoia (assessed using the
Schedules for Clinical Assessment in Neuropsychiatry23); score
of greater than 29 on the Green et al Paranoid Thoughts Scale
(GPTS) Part B, the Persecutory subscale24; a diagnosis of schizo-
phrenia spectrum psychosis (codes F20-29 from the Interna-
tional Statistical Classification of Diseases and Related Health
Problems, Tenth Revision)25; capacity to provide informed con-
sent; and sufficient English to participate in trial processes.
Participants were excluded if they had profound visual or hear-
ing impairment, were unable to engage in assessments, were
currently receiving psychological therapy for paranoia, and had
a primary diagnosis of substance use disorder, personality dis-
order, organic syndrome, or learning disability.
Randomization and Masking
After baseline assessment, we randomly assigned (1:1) eli-
gible patients using a secure, independent, web-based ser-
vice hosted by King’s Clinical Trials Unit. Randomly varying
sized blocks were used and stratified by site and baseline para-
noia (median split of ≥62 on GPTS Part B score24). Research as-
sessors were masked to allocation. The site coordinators (T.W.,
M.R.-C., A.M., C.S., and N.C.) conducted randomization and
informed participants. If unmasking occurred, reallocation to
another rater occurred when operationally feasible. Breaks in
masking were recorded.
Interventions
SlowMo is a digitally supported CBTp consisting of 8 indi-
vidual, face-to-face sessions (60-90 minutes) in accordance
with a clinical manual that was delivered within 12 weeks. The
intervention builds awareness of unhelpful fast thinking and
supports individualized formulation. SlowMo then assists
people with slowing down for a moment to find ways of feeling
safer. Sessions are assisted by the SlowMo web app delivered
using a touchscreen laptop, with interactive features includ-
ing information, animated vignettes, games, and personal-
ized thought bubbles. The web app synchronizes to a native
Key Points
Question Can a brief blended digital therapy targeting reasoning
(SlowMo) improve paranoia for adults with psychosis when added
to usual care?
Findings This randomized clinical trial of 361 individuals with
clinical paranoia did not demonstrate that SlowMo therapy
reduced the primary outcome of self-reported paranoia at
24 weeks compared with usual care only, although secondary
beneficial effects were found on this measure at 12 weeks.
Self-reported persecution and observer-rated paranoia were
improved at both points.
Meaning SlowMo, a digitally supported reasoning intervention,
indicated a beneficial effect on paranoia; further work to optimize
the effects of SlowMo is warranted.
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android mobile app providing access in daily life to SlowMo
strategies and individualized safer-thought bubbles.14,26 A de-
vice was provided to all participants. Behavioral work out-
side the clinic room was encouraged, with the aim of practic-
ing strategies. Therapy was delivered in clinic settings or at
home (eMethods 1 and eFigure 1 in Supplement 2 give fur-
ther details on the intervention).
Therapists included 11 trained doctoral-level psycholo-
gists (M.R.-C., T.W., A.M., C.S., and N.C. and 6 others), with
therapists supervised weekly using recorded sessions. Therapy
uptake was assessed by number and duration of sessions at-
tended, with fidelity to the clinical manual defined as no more
than 1 web app component missed per session (mean calcu-
lated across all attended sessions). Mobile app adherence was
operationalized as at least 1 home screen interaction after a
minimum of 3 therapy sessions and was recorded by system
analytics (eMethods 2 in Supplement 2).
Treatment as usual was delivered according to UK na-
tional and local service guidelines and typically involved an-
tipsychotic therapy, contact with a mental health worker, and
outpatient psychiatric appointments. Participation did not al-
ter pharmacologic or psychosocial treatment decisions (re-
corded in both groups using the modified Client Service Re-
ceipt Inventory27).
Measurements
Assessments were performed at 0 (baseline), 12 weeks (post-
intervention), and 24 weeks (follow-up). Blinded assessors
conducted enrollment and assessments at clinics or in partici-
pants’ homes. Participants were compensated £20 (approxi-
mately US $28) at each point.
Outcomes
The primary outcome was self-reported paranoia severity at
24 weeks, measured by the GPTS total score24 (range, 32-160,
with higher scores indicating more severe paranoia). The GPTS
consists of two 16-item subscales assessing ideas of social ref-
erence (Part A) and persecution (Part B) during the previous
month, with reported scores being secondary outcomes. De-
tail on all measures is provided in Supplement 1 and eMethods
3 and 4 in Supplement 2. Secondary paranoia measures also
consisted of 2 observer-rated scales: the Psychotic Symptom
Rating Scales (PSYRATS) delusions subscale,28 scored as a total
and as 2 factors (conviction and distress29), and individual
persecutory delusions and ideas of reference items from the
Scales for Assessment of Positive Symptoms (SAPS).30 We also
assessed outcomes on the Revised GPTS (R-GPTS)31 (total and
subscale scores); this revised measure was published during
the trial and was added to the statistical analysis plan before
statistical analysis commenced (Supplement 1). It consists of
2 scales assessing thinking relevant to paranoia based on the
original items: ideas of social reference (8 items) and perse-
cution (10 items).
Reasoning was assessed as an outcome and as a potential
mediator by 2 established methods of assessing belief flexibil-
ity relating to delusions8: possibility of being mistaken (self-
rated 0%-100% and observer-rated yes or no) from the Maud-
sley Assessment of Delusions Schedule32 and alternative
explanations from the Explanations of Experiences interview,33
with increased flexibility being desirable; and by the JTC
Beads Task,7 versions 85:15 and 60:40. The Fast and Slow
Thinking Questionnaire34 (previously the TAPS26), consist-
ing of 2 scales, one assessing fast (intuitive) thinking and one
measuring slow (analytic) thinking, was included as a reason-
ing outcome but was not prespecified as a hypothesized me-
diator. Other secondary outcomes were well-being (the
Warwick-Edinburgh Mental Well-being Scale35), quality of
life (the Manchester Short Assessment of Quality of Life36),
self and other schemas (the Brief Core Schema Scales37),
and worry (the Penn State Worry Questionnaire38). Adverse
events were actively monitored throughout the study until the
24-week follow-up.
Statistical Analysis
We powered the study to detect a 10-point reduction in the
GPTS total score (effect size, 0.40) and accounted for the par-
tial nested design owing to therapist clustering in the SlowMo
arm.39 With 1:1 allocation and a statistical significance level of
2-tailed P < .05, a simple 2-tailed t test with 150 people per
group had 90% power to detect an effect size of 0.40 and 80%
power for an effect size of 0.35. To allow for 20% attrition, we
aimed to recruit 360 patients at baseline split equally across
3 sites. All analyses were performed using the intention-to-
treat population. Statisticians (R.E. and K.J.) were only un-
blinded after database lock, and the statistical analysis was per-
formed unblinded owing to the need to account for therapist
effects in the SlowMo arm. No interim analysis was per-
formed. All analyses were conducted in Stata, version 16.0
(StataCorp LLC).40
To test the primary hypothesis that the intervention
would reduce paranoia severity during the 24-week study,
we fitted a linear mixed model allowing for clustering by par-
ticipants and therapists to the repeated measures of the
GPTS with fixed effects of randomization, time, time by ran-
domization interaction, site, paranoia severity (stratifier),
and baseline GPTS. The treatment effect (adjusted between-
group mean difference) was estimated from the model for
each point separately. All secondary outcome measures were
analyzed using linear mixed models for continuous out-
comes and logistic mixed models for binary outcomes.
Cohen d effect sizes at 12 and 24 weeks were calculated as
the adjusted mean difference divided by the sample SD
of the outcome at baseline and are shown in a forest plot.
Mediation analysis used parametric regression models,
whereas moderation analyses were conducted by adding
interaction terms between randomized groups and a set of
prespecified moderators; further detail of the moderation
and mediation analyses and the methods and results of a
compliance-adjusted analysis are provided in eMethods 5, 6,
and 8 in Supplement 2.
Missing data on measures were prorated if more than 90%
of items were completed; otherwise the measure was consid-
ered missing. We checked for covariates associated with miss-
ing outcomes by comparing responders with nonresponders
on key baseline variables. Maximum likelihood estimation
in the mixed models accounted for missing outcome data
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under a missing-at-random assumption, conditional on the
covariates included in the model.
Results
Of 604 people assessed for eligibility, 362 were recruited; 181
were randomized to the SlowMo group and 181 to the TAU
group (Figure 1). One participant in the TAU group withdrew
consent to use data after randomization. The final sample
was therefore 361 participants.
Data on the primary outcome were available on 328 par-
ticipants (90.6%) at 12 weeks and 332 (92.0%) at 24 weeks. Un-
masking without replacement of an assessor occurred for 22
participants (6.7%) at 12 weeks and 19 participants (5.7%) at
24 weeks (eTable 1 in Supplement 2).
Participant baseline characteristics and stratification fac-
tors (paranoia severity and site) are shown in Table 1. Typical
of samples with persisting psychosis, participants were pre-
dominantly male (252 [69.8%]) and White (249 [69.0%]), with
a mean (SD) age of 42.6 (11.6) years. Other clinical character-
istics (diagnosis, years in contact with services, and medica-
tion equivalent doses) were also unexceptional. There were no
marked differences between the groups. Most participants
had severe paranoia; 170 (94.4%) in the TAU arm and 169
(93.4%) in the SlowMo arm met criteria31 for likely presence
of persecutory delusions on the GPTS (eTable 2 in Supple-
ment 2). Baseline characteristics are also shown by site in
eTable 3 in Supplement 2. eTable 4 in Supplement 2 shows
baseline values of clinical and cognitive measures examined
as putative moderators.
The mean (SD) number of SlowMo sessions attended was
6.8 (2.6), increasing to 7.3 (1.9) for those attending 1 or more
sessions. Among the 181 participants in the SlowMo arm, 145
(80.1%) completed all 8 therapy sessions, 13 (7.2%) attended
no sessions, and 23 (12.7%) discontinued therapy between ses-
sions 1 and 7. Mean (SD) session duration, including behav-
ioral work, was 75 (29) minutes. Therapy fidelity was high; of
the 168 individuals who attended at least 1 session, 159 (94.6%)
met a priori criteria for web app delivery, and 100 of 140 (71.4%)
met adherence criteria for mobile app use.
Descriptive statistics, between-group mean differences and
their associated P values and 95% CIs, and standardized ef-
fect sizes for all primary and secondary paranoia outcomes are
given in Table 2. Figure 2 shows standardized effect sizes for
continuous variables as a forest plot (eFigure 2 in Supplement 2
gives a forest plot of binary secondary outcomes). SlowMo plus
TAU was not associated with greater reductions than TAU alone
in the primary outcome of GPTS total paranoia score at 24
weeks (Cohen d, 0.20; 95% CI, −0.02 to 0.40; P = .06). At 12
weeks, SlowMo plus TAU was associated with greater reduc-
tions than TAU alone in GPTS total score (Cohen d, 0.30;
95% CI, 0.09-0.51; P = .005), Part A score (Cohen d, 0.22;
95% CI, 0.06-0.39; P = .009), and Part B score (Cohen d,
0.32; 95% CI, 0.08-0.56; P = .009). At 24 weeks, SlowMo was
significantly associated with lower Part B score (Cohen d, 0.25;
95% CI, 0.01-0.49; P = .04) but not Part A score (Cohen d,
0.12; 95% CI, −0.05 to 0.28; P = .18).
SlowMo was also associated with improvements in ob-
server-rated measures of persecutory delusions, including
PSYRATS Delusions subscale score at 12 (Cohen d, 0.47;
95% CI, 0.17-0.78; P = .002) and 24 (Cohen d, 0.50; 95% CI,
0.20-0.80; P = .001) weeks and SAPS Persecutory Delusions
subscale score at 12 (Cohen d, 0.43; 95% CI, 0.03-0.84; P = .04)
and 24 (Cohen d, 0.54; 95% CI, 0.14-0.94; P = .009) weeks.
The reduction in paranoia on the R-GPTS total score was sig-
nificant at both points (Cohen d at 12 weeks, 0.33 [95% CI, 0.12-
0.54; P = .002]; Cohen d at 24 weeks, 0.23 [95% CI, 0.02-
0.44; P = .03]), as were the reductions on the PSYRATS distress
(Cohen d at 12 weeks, 0.50 [95% CI, 0.17-0.82; P = .003];
Cohen d at 24 weeks, 0.43 [95% CI, 0.11-0.76; P = .009]) and
conviction (Cohen d at 12 weeks, 0.31 [95% CI, 0.06-0.56;
P = .01]; Cohen d at 24 weeks, 0.43 [95% CI, 0.18-0.68;
P = .001]) subscale scores. Referential ideas assessed using
GPTS Part A, R-GPTS Reference, and SAPS Ideas of Reference
subscale scores showed less consistent effects, with signifi-
cant effects either at 12 weeks or 24 weeks but not both.
Treatment effects were found for some but not all reason-
ing measures. Belief flexibility (possibility of being mistaken)
Figure 1. Trial Profile
1021 Potential participants referred
to SlowMo
604 Assessed for eligibility
181 Randomized to SlowMo 181 Randomized to TAU
166 With data at 12 wk 163 With data at 12 wk
162 With data at 24 wk 172 With data at 24 wk













145 Did not meet inclusion
criteria
65 Refused to participate
13 Unable to collect data
2 Withdrawn




15 Unable to collect data
TAU indicates treatment as usual.
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Table 1. Baseline Characteristics of the Intention-to-Treat Population
Characteristic
Study arma
SlowMo (n = 181) TAU (n = 180) Overall (N = 361)
Age, mean (SD), y 43.1 (11.7) 42.2 (11.6) 42.6 (11.6)
Sex
Male 132 (72.9) 120 (66.7) 252 (69.8)
Female 49 (27.1) 60 (33.3) 109 (30.2)
Marital status
Single 145 (80.1) 137 (76.1) 282 (78.1)
Cohabiting 6 (3.3) 6 (3.3) 12 (3.3)
Married or civil partnership 22 (12.2) 24 (13.3) 46 (12.7)
Divorced 7 (3.9) 10 (5.6) 17 (4.7)
Widowed 1 (0.6) 3 (1.7) 4 (1.1)
Self-defined race/ethnicity
White 120 (66.3) 129 (71.7) 249 (69.0)
Black Caribbean 9 (5.0) 9 (5.0) 18 (5.0)
Black African 12 (6.6) 10 (5.6) 22 (6.1)
Black other 16 (8.8) 12 (6.7) 28 (7.8)
Indian 0 3 (1.7) 3 (0.8)
Pakistani 4 (2.2) 4 (2.2) 8 (2.2)
Chinese 1 (0.6) 0 1 (0.3)
Other 19 (10.5) 12 (6.7) 31 (8.6)
Missing 0 1 (0.6) 1 (0.3)
Highest level of schooling
Primary school 4 (2.2) 3 (1.7) 7 (1.9)
Secondary, no examinations or qualifications 30 (16.6) 34 (18.9) 64 (17.7)
Secondary O/CSE equivalent 50 (27.6) 51 (28.3) 101 (28.0)
Secondary A-level equivalent 23 (12.7) 16 (8.9) 39 (10.8)
Vocational education or college 43 (23.8) 44 (24.4) 87 (24.1)
University degree or professional qualification 31 (17.1) 30 (16.7) 61 (16.9)
Missing 0 2 (1.1) 2 (0.6)
Current working status
Unemployed 141 (77.9) 150 (83.3) 291 (80.6)
Employed
Full-time 8 (4.4) 8 (4.4) 16 (4.4)
Part-time 15 (8.3) 14 (7.8) 29 (8.0)
Self-employed 4 (2.2) 2 (1.1) 6 (1.7)
Retired 10 (5.5) 2 (1.1) 12 (3.3)
Student 1 (0.6) 3 (1.7) 4 (1.1)
Housewife or househusband 2 (1.1) 1 (0.6) 3 (0.8)
Normal living situation
Alone 108 (59.7) 103 (57.2) 211 (58.4)
With partner 19 (10.5) 28 (15.6) 47 (13.0)
With parents 25 (13.8) 30 (16.7) 55 (15.2)
With other relatives 4 (2.2) 4 (2.2) 8 (2.2)
With others 25 (13.8) 15 (8.3) 40 (11.1)
Site
London 66 (36.5) 64 (35.6) 130 (36.0)
Oxford 49 (27.1) 50 (27.8) 99 (27.4)
Sussex 66 (36.5) 66 (36.7) 132 (36.6)
GPTS Part B score (stratification factor)
<62 110 (60.8) 109 (60.6) 219 (60.7)
≥62 71 (39.2) 71 (39.4) 142 (39.3)
(continued)
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improved at 12 (Cohen d, 0.29; 95% CI, 0.09-0.49; P = .004)
and 24 (Cohen d, 0.28; 95% CI, 0.08-0.49; P = .005) weeks but
alternative explanations did not. The binary measure of the
possibility of being mistaken was significant at 12 but not 24
weeks. Jumping to conclusions did not improve (with 1 sig-
nificant finding, beads drawn at 12 weeks). The fast-thinking
scale of the Fast and Slow Thinking Questionnaire showed im-
provements at both time points, and the slow-thinking scale
showed improvement at 24 weeks. Significant improve-
ments were found for SlowMo in well-being (Cohen d at 24
weeks, 0.32; 95% CI, 0.12-0.51; P = .001), quality of life (Co-
hen d at 24 weeks, 0.27; 95% CI, 0.09-0.45; P = .003), worry
(Cohen d at 12 weeks, 0.27 [95% CI, 0.10-0.44; P = .002];
Cohen d at 24 weeks, 0.21 [95% CI, 0.05-0.38; P = .01]),
and self-concept (Cohen d for negative self at 12 weeks, 0.17
[95% CI, 0.01-0.34; P = .04]; Cohen d for negative self at 24
weeks, 0.21 [95% CI, 0.04-0.38; P = .01]; Cohen d for positive
self at 24 weeks, 0.20 [95% CI, 0.06-0.35; P = .006]) (Table 3
and Figure 2).
The moderation analysis (eTable 5 in Supplement 2)
revealed no differential effects on paranoia as measured by
the GPTS or R-GPTS.31 There were 2 moderation effects (on
PSYRATS), at P < .05. However, given the number of tests,
this finding may have occurred by chance.
The mediation analysis results on the GPTS, R-GPTS, and
PSYRATS at 12 and 24 weeks are shown in eTables 6 to 8 in
Supplement 2. The possibility of being mistaken (0%-100%)32
and worry38 mediated the treatment effects on all paranoia out-
comes at 12 and 24 weeks. Approximately 40% of the total
effect was mediated through each mediator at 12 weeks and
56% at 24 weeks.
Fifty-four adverse events were reported, of which 51 were
serious, occurring in 19 participants in the SlowMo group and
21 in the TAU group; no deaths were recorded (eMethods 7 and
eTable 9 in Supplement 2). A compliance-adjusted analysis
showed significant treatment effects of SlowMo therapy on the
primary outcome compared with TAU in those adherent to
treatment at all points, with treatment effects increasing as
the number of sessions increased (eTable 10 in Supple-
ment 2). Data on concomitant treatments and service use
are shown in eMethods 9 and eTables 11 and 12, respectively,
in Supplement 2.
Discussion
Treatment with SlowMo, a brief blended digital therapy, did
not result in significant improvements in the primary out-
come of total GPTS paranoia score at 24 weeks. However, the
pattern of results indicates that SlowMo had a beneficial ef-
fect on paranoia in general. Effects on total self-rated GPTS
paranoia after treatment and on self-rated GPTS persecution
during the 24-week study and significant sustained moder-
ate effects on all observer-rated measures of persecutory de-
lusions were seen. SlowMo treatment was associated with im-
provements in reasoning, in belief flexibility (possibility of
being mistaken), and Fast and Slow Thinking Questionnaire
scores. Change in both belief flexibility and worry mediated
improvements in paranoia. There were effects on outcomes
prioritized at the design stage by service-user consultants41
in well-being, self-esteem, quality of life, and worry, with the
most consistent change at 24 weeks. Therapy uptake and ad-
herence were high. Treatment effects were not moderated by
clinical or demographic variables, indicating benefits regard-
less of cognitive capacity, symptoms, or caregiver relation-
ships. There was no evidence of the intervention being
harmful, with similar numbers of serious adverse events in
both groups.
Although GPTS effects were small, most met the thresh-
old of P < .05, suggesting consistent effects on secondary self-
reported paranoia outcomes. Of note, the effects for the ob-
server-rated and widely used PSYRATS total score were in the
moderate range. Although adjustment of type I error in the
reporting of secondary outcomes in clinical trials is not
mandated,42 this improvement (at P < .001) would remain
significant at 24 weeks even if a conservative adjustment for
multiple testing were to be applied. In addition to reduced
PSYRATS conviction scores, the clinically important target of
distress also showed a sustained reduction. Taken together,
the secondary paranoia outcomes indicate small to moderate
Table 1. Baseline Characteristics of the Intention-to-Treat Population (continued)
Characteristic
Study arma
SlowMo (n = 181) TAU (n = 180) Overall (N = 361)
Diagnosis
Schizophrenia 116 (64.1) 109 (60.6) 225 (62.3)
Schizoaffective disorder 30 (16.6) 34 (18.9) 64 (17.7)
Delusional disorder 3 (1.7) 3 (1.7) 6 (1.7)
Psychosis (other) 32 (17.7) 34 (18.9) 66 (18.3)
Time in contact with services, y
<1 7 (3.9) 6 (3.3) 13 (3.6)
1-5 22 (12.2) 33 (18.3) 55 (15.2)
6-10 40 (22.1) 44 (24.4) 84 (23.3)
11-20 70 (38.7) 70 (38.9) 140 (38.8)
>20 42 (23.2) 27 (15.0) 69 (19.1)
Chlorpromazine-equivalent dose of antipsychotic drug,
mean (SD), mg/d
452.96 (399.45) 519.97 (419.80) 486.37 (410.53)




TAU, treatment as usual.
a Unless otherwise indicated, data are
expressed as number (percentage)
of patients.
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Table 2. Primary and Secondary Paranoia Outcomes
Outcome
SlowMo groupa TAU groupa
Adjusted mean difference (SE)
[95% CI] P value








Baseline 104.7 (27.6) 180 105.9 (26.0) 179 NA NA NA
24 wk 81.7 (31.6) 161 86.3 (33.2) 171 −5.27 (2.84) [−10.83 to 0.29] .06 0.20 (−0.02 to 0.40)
Secondary
GPTS total score
Baseline 104.7 (27.6) 180 105.9 (26.0) 179 NA NA NA
12 wk 84.8 (30.8) 165 92.5 (33.1) 163 −8.06 (2.85) [−13.64 to −2.48] .005 0.30 (0.09 to 0.51)
GPTS Part A score
Baseline 48.6 (15.9) 181 50.3 (15.1) 179 NA NA NA
12 wk 40.2 (14.9) 165 44.2 (15.8) 163 −3.49 (1.34) [−6.12 to −0.86] .009 0.22 (0.06 to 0.39)
24 wk 39.2 (15.0) 161 42.0 (15.8) 172 −1.79 (1.34) [−4.41 to −0.83] .180 0.12 (−0.05 to 0.28)
GPTS Part B score
Baseline 56.2 (14.4) 180 55.9 (13.8) 180 NA NA NA
12 wk 44.6 (18.1) 166 48.2 (18.7) 163 −4.51 (1.71) [−7.87 to −1.15] .009 0.32 (0.08 to 0.56)
24 wk 42.2 (18.2) 161 45.1 (18.9) 171 −3.53 (1.71) [−6.89 to −0.18] .04 0.25 (0.01 to 0.49)
R-GPTS total score
Baseline 40.7 (15.4) 179 41.5 (14.8) 180 NA NA NA
12 wk 29.6 (17.2) 166 34.3 (18.6) 163 −5.00 (1.61) [−8.16 to −1.86] .002 0.33 (0.12 to 0.54)
24 wk 27.5 (17.6) 160 31.1 (18.6) 169 −3.42 (1.61) [−6.57 to −0.27] .03 0.23 (0.02 to 0.44)
R-GPTS social reference score
Baseline 16.0 (7.8) 180 17.1 (8.2) 180 NA NA NA
12 wk 11.9 (7.6) 166 14.2 (8.1) 163 −2.05 (0.70) [−3.42 to −0.68] .003 0.26 (0.08 to 0.43)
24 wk 11.3 (7.6) 160 13.1 (8.0) 172 −1.15 (0.70) [−2.51 to 0.22] .099 0.14 (−0.03 to 0.31)
R-GPTS persecution score
Baseline 24.7 (9.3) 180 24.4 (8.7) 180 NA NA NA
12 wk 17.7 (11.1) 166 20.1 (11.7) 163 −2.97 (1.07) [−5.07 to −0.88] .005 0.33 (0.10 to 0.56)
24 wk 16.3 (11.2) 161 18.0 (11.6) 169 −2.25 (1.07) [−4.34 to −0.16] .04 0.25 (0.02 to 0.48)
PSYRATS total score
Baseline 16.5 (3.3) 180 16.2 (3.1) 180 NA NA NA
12 wk 13.2 (4.9) 166 14.5 (5.0) 162 −1.53 (0.50) [−2.50 to −0.56] .002 0.47 (0.17 to 0.78)
24 wk 12.5 (5.2) 161 14.0 (5.5) 171 −1.62 (0.49) [−2.59 to −0.65] .001 0.50 (0.20 to 0.80)
PSYRATS distress score
Baseline 8.1 (1.8) 181 7.9 (1.7) 180 NA NA NA
12 wk 6.3 (2.8) 166 7.0 (2.8) 162 −0.87 (0.29) [−1.44 to −0.30] .003 0.50 (0.17 to 0.82)
24 wk 6.0 (3.0) 161 6.8 (3.0) 171 −0.76 (0.29) [−1.32 to −0.19] .009 0.43 (0.11 to 0.76)
PSYRATS conviction score
Baseline 8.4 (2.0) 180 8.3 (1.9) 180 NA NA NA
12 wk 6.9 (2.5) 166 7.4 (2.6) 163 −0.62 (0.25) [−1.11 to −0.13] .01 0.31 (0.06 to 0.56)
24 wk 6.4 (2.5) 161 7.2 (2.8) 172 −0.84 (0.25) [−1.33 to −0.35] .001 0.43 (0.18 to 0.68)
SAPS persecutory delusions
score
Baseline 3.5 (0.8) 181 3.4 (0.9) 180 NA NA NA
12 wk 2.8 (1.3) 164 3.0 (1.3) 161 −0.37 (0.18) [−0.71 to −0.03] .04 0.43 (0.03 to 0.84)
24 wk 2.5 (1.5) 161 2.8 (1.4) 171 −0.46 (0.18) [−0.80 to −0.12] .009 0.54 (0.14 to 0.94)
SAPS ideas and delusions of
reference score
Baseline 2.5 (1.8) 181 2.7 (1.7) 180 NA NA NA
12 wk 2.2 (1.9) 165 2.4 (1.8) 161 −0.18 (0.19) [−0.55 to 0.19] .35 0.10 (−0.11 to 0.31)
24 wk 1.9 (1.9) 160 2.4 (1.9) 171 −0.41 (0.19) [−0.79 to −0.04] .03 0.24 (0.02 to 0.45)
Abbreviations: GPTS, Green et al Paranoid Thoughts Scale; NA, not applicable;
PSYRATS, Psychotic Symptom Rating Scales; R-GPTS, Revised GPTS;
SAPS, Scale for the Assessment of Positive Symptoms; TAU, treatment as usual.
a Low score indicates better outcomes.
b Negative effects indicate benefit of SlowMo compared with TAU.
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effects that were equal to or greater than rates reported in
meta-analyses of longer-term CBTp for delusions.2,43 How-
ever, given this overall pattern of results, the absence of an
effect on the primary outcome of GPTS total score at 24 weeks
and the failure to reach the a priori threshold for clinical im-
portance merit further consideration. Examination of the
Figure 2. Primary and Secondary Outcomes of SlowMo
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Secondary: hypothesized reasoning mediators
FaST fast scale 0.30 (0.09 to 0.49)
FaST slow scale 0.21 (0.02 to 0.40)
Possibility of being mistaken (0%-100%) 0.28 (0.08 to 0.49)
24 wkB
0.29 (0.09 to 0.49)
0.14 (–0.05 to 0.33)
0.34 (0.03 to 0.44)
0.08 (–0.10 to 0.25)
0.06 (–0.11 to 0.22)
0.04 (–0.15 to 0.22)
0.06 (–0.09 to 0.20)
0.17 (0.01 to 0.34)
0.27 (0.10 to 0.44)
0.18 (–0.02 to 0.37)
0.10 (–0.11 to 0.31)
0.43 (0.03 to 0.84)
0.31 (0.06 to 0.56)
0.50 (0.17 to 0.82)
0.47 (0.17 to 0.78)
0.33 (0.10 to 0.56)
0.26 (0.08 to 0.43)
0.33 (0.12 to 0.54)
0.32 (0.08 to 0.56)
0.22 (0.06 to 0.39)
0.30 (0.09 to 0.51)
0.27 (0.09 to 0.45)
0.07 (–0.10 to 0.23)
0.03 (–0.16 to 0.21)
0.20 (0.06 to 0.35)
0.21 (0.04 to 0.38)
0.21 (0.05 to 0.38)
0.32 (0.12 to 0.51)
0.24 (0.02 to 0.45)
0.54 (0.14 to 0.94)
0.43 (0.18 to 0.68)
0.43 (0.11 to 0.76)
0.50 (0.20 to 0.80)
0.25 (0.02 to 0.48)
0.14 (–0.03 to 0.31)
0.23 (0.02 to 0.44)
0.25 (0.01 to 0.49)
0.12 (–0.05 to 0.28)
Markers represent point estimates,
with horizontal lines representing
95% CIs. BCSS indicates Brief Core
Schema Scales; FaST, Fast and Slow
Thinking Questionnaire; GPTS, Green
et al Paranoid Thoughts Scales;
MANSA, Manchester Short
Assessment of Quality of Life;
PSWQ, Penn State Worry
Questionnaire; PSYRATS, Psychotic
Symptom Rating Scales;
R-GPTS, Revised GPTS; SAPS, Scale
for the Assessment of Positive
Symptoms; TAU, treatment as usual;
and WEMWBS, Warwick-Edinburgh
Mental Well-being Scale.
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Table 3. Secondary Outcomes and Hypothesized Mediators
Outcome
SlowMo groupa TAU groupa
Adjusted mean difference (SE)






Baseline 39.3 (9.1) 179 40.5 (8.7) 175 NA NA
12 wk 42.2 (9.4) 164 41.6 (9.1) 157 1.56 (0.89) [−0.18 to 3.30] .08
24 wk 43.3 (11.0) 157 41.2 (9.6) 165 2.82 (0.89) [1.08 to 4.56] .001
PSWQ score
Baseline 56.9 (10.8) 179 56.6 (10.1) 175 NA NA
12 wk 53.2 (11.6) 158 55.4 (11.5) 157 −2.81 (0.90) [−4.57 to −1.04] .002
24 wk 52.2 (11.6) 154 54.5 (11.5) 163 −2.24 (0.90) [−4.00 to −0.48] .01
BCSS negative self score
Baseline 9.9 (5.8) 181 10.3 (5.5) 178 NA NA
12 wk 9.0 (6.0) 162 10.0 (6.0) 159 −0.98 (0.48) [−1.92 to −0.04] .04
24 wk 8.4 (5.9) 160 9.7 (5.8) 167 −1.19 (0.48) [−2.12 to −0.25] .01
BCSS positive self scorec
Baseline 10.7 (5.6) 181 10.8 (5.4) 178 NA NA
12 wk 11.5 (5.6) 164 11.5 (5.6) 159 0.33 (0.41) [−0.48 to 1.13] .43
24 wk 12.5 (5.5) 159 11.6 (5.8) 168 1.11 (0.41) [0.31 to 1.92] .006
BCSS negative other score
Baseline 13.3 (6.1) 181 13.3 (5.8) 178 NA NA
12 wk 12.9 (6.1) 163 13.0 (6.0) 159 −0.21 (0.55) [−1.30 to 0.88] .70
24 wk 12.6 (6.2) 159 12.7 (6.3) 168 −0.16 (0.55) [−1.25 to 0.92] .77
BCSS positive other scorec
Baseline 11.6 (5.2) 180 11.1 (4.9) 177 NA NA
12 wk 12.2 (5.1) 164 11.8 (4.8) 159 0.28 (0.42) [−0.55 to 1.12] .50
24 wk 12.4 (4.8) 158 12.1 (4.8) 168 0.34 (0.42) [−0.49 to 1.17] .42
MANSA scorec
Baseline 46.8 (9.9) 161 48.1 (10.2) 164 NA NA
12 wk 48.1 (10.7) 145 48.9 (10.6) 146 0.76 (0.91) [−1.02 to 2.55] .40
24 wk 50.5 (11.7) 135 49.1 (9.5) 148 2.75 (0.92) [0.94 to 4.55] .003
Possibility of being mistaken
(0%-100%)c
Baseline 34.6 (30.9) 181 35.1 (31.0) 180 NA NA
12 wk 48.9 (32.2) 165 39.9 (33.2) 161 9.02 (3.16) [2.83 to 15.21] .004
24 wk 45.3 (31.8) 161 37.7 (31.1) 172 8.88 (3.16) [2.70 to 15.07] .005
Possibility of being mistaken,
No. yes/no (% yes/% no)c
Baseline 105/76 (58/42) NA 106/74 (59/41) NA NA NA
12 wk 124/41 (75/25) NA 100/61 (62/38) NA 3.83 (1.53 to 9.59)d .004
24 wk 105/56 (65/35) NA 100/72 (58/42) NA 2.01 (0.86 to 4.70)d .11
Alternative explanations,
No. yes/no (% yes/% no)c
Baseline 79/102 (44/56) NA 85/94 (48/52) NA NA NA
12 wk 90/74 (55/45) NA 78/83 (48/52) NA 1.74 (0.90 to 3.36)d .10
24 wk 87/73 (54/46) NA 87/82 (52/48) NA 1.33 (0.70 to 2.55)d .39
JTC version 85:15,
No. yes/no (% yes/% no)
Baseline 103/77 (57/43) NA 83/96 (46/54) NA NA NA
12 wk 70/95 (42/58) NA 68/91 (42/58) NA 0.71 (0.31 to 1.62)d .42
24 wk 55/105 (34/66) NA 62/107 (37/63) NA 0.58 (0.25 to 1.34)d .20
JTC version 85:15 (No. of beads)
Baseline 3.8 (4.4) NA 3.9 (4.0) NA NA NA
12 wk 4.3 (4.3) NA 4.1 (3.9) NA 0.39 (0.43) [−0.45 to 1.22] .37
24 wk 5.2 (4.8) NA 4.1 (3.3) NA 0.99 (0.42) [0.16 to 1.83] .02
(continued)
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results and the GPTS subscales constituting the total score
indicates that persecutory beliefs showed stronger effects
across a range of measures, whereas milder referential ideas
(self or observer rated) did not show consistent improve-
ment. One potential explanation may be that as persecutory
beliefs improved, they changed into milder ideas of reference
(thus shifting down the hierarchy of paranoid beliefs44,45),
but that the therapy prevented such ideas and their experien-
tial components from being elaborated into paranoid fears of
intentional harm. Given this finding, we believe that future it-
erations of SlowMo therapy should enhance work on referen-
tial ideas.
High uptake, fidelity, and adherence and the absence of
moderation by baseline characteristics suggest that the inclu-
sive, human-centered design facilitated engagement across a
wide range of users and settings, which is crucial to real-
world implementation.15,16 Usability and acceptability will
be the subjects of future studies. Barriers to accessing psycho-
logical therapy for paranoia are widely reported,46 with effec-
tive, usable brief treatments such as SlowMo offering a poten-
tial solution.
A second goal was to evaluate reasoning as a mechanism.
Improvements were observed in belief flexibility. Consistent
with a proof-of-concept study,9 the possibility of being mis-
taken mediated the change in paranoia, explaining 36% to 56%
of the variance after the intervention and at follow-up. In con-
trast, JTC showed little evidence of change. This finding, to-
gether with meta-analytic results,47 suggests that JTC may
be associated with vulnerability to persecutory beliefs but be
relatively unresponsive to change over time. This evolving un-
derstanding supports foregrounding the promotion of slow
thinking and greater flexibility with the aim of generating com-
pensatory strategies for real-world fast thinking.8
Worry also mediated paranoia reduction, with a similar
proportion of the variance explained by the mediation by be-
lief flexibility. This was not hypothesized because worry was
not explicitly targeted in SlowMo. However, given that worry
causes paranoia21 and that SlowMo altered worry, the finding
suggests that worry reduction plausibly constitutes part of the
treatment route for SlowMo. Of note, SlowMo shares features
with worry interventions.21 Both involve noticing thoughts, de-
centering, and refocusing attention. Furthermore, the extent
to which worry and belief flexibility are independent routes
to change or whether other mechanisms for treatment ef-
fects, such as the parallel improvements in self-concept and
well-being, might occur could not be determined in the present
study. Our original hypotheses derived from a theory of change
in which the primary process underpinning SlowMo was via
reasoning. However, the evidence from this study suggests the
potential for other processes also to be involved in treatment
effects. Our cognitive model of paranoia proposes multifac-
torial causality, particularly highlighting both reasoning and
emotional processes.48 We plan additional investigations of
these and other potential mechanisms to inform further causal
understanding of paranoia.
Limitations
This study has limitations. The trial design did not control for
effects of time with a therapist, with TAU being selected as the
comparator condition. There is a low penetration of evidence-
Table 3. Secondary Outcomes and Hypothesized Mediators (continued)
Outcome
SlowMo groupa TAU groupa
Adjusted mean difference (SE)





JTC version 60:40 (yes or no)
Baseline 72/108 (40/60) NA 59/120 (33/67) NA NA NA
12 wk 47/118 (29/71) NA 42/117 (26/74) NA 0.82 (0.26 to 2.51)d .72
24 wk 43/117 (27/73) NA 44/125 (26/74) NA 0.69 (0.22 to 2.18)d .53
JTC version 60:40 (No. of beads)
Baseline 5.7 (5.4) NA 5.7 (5.1) NA NA NA
12 wk 7.0 (5.7) NA 6.8 (5.4) NA 0.28 (0.49) [−0.68 to 1.25] .56
24 wk 7.0 (5.2) 6.5 (4.9) 0.49 (0.49) [−0.47 to 1.45] .32
FaST fast scale score
Baseline 16.9 (4.7) 174 16.7 (4.3) 169 NA NA
12 wk 15.3 (4.9) 165 16.2 (5.0) 160 −1.07 (0.47) [−1.98 to −0.16] .02
24 wk 15.0 (4.4) 160 16.2 (5.1) 168 −1.33 (0.46) [−2.23 to −0.42] .004
FaST slow scale scorec
Baseline 19.9 (4.7) 174 19.7 (4.8) 169 NA NA
12 wk 20.3 (4.8) 165 19.3 (4.8) 160 0.66 (0.45) [−0.22 to 1.55] .14
24 wk 20.3 (4.4) 160 19.3 (4.8) 168 1.00 (0.45) [0.12 to 1.88] .03
Abbreviations: BCSS, Brief Core Schema Scale; FaST, Fast and Slow Thinking
Questionnaire; JTC, jumping to conclusions; MANSA, Manchester Short
Assessment of Quality of Life; NA, not applicable; PSWQ, Penn State Worry
Questionnaire; TAU, treatment as usual; WEMWBS, Warwick-Edinburgh Mental
Well-being Scale.
a Unless otherwise indicated, low score indicates better outcomes.
b Unless otherwise indicated, negative effects indicate benefit of SlowMo
compared with TAU.
c High score indicates better outcomes; positive effects indicate benefit of
SlowMo compared with TAU.
d Odds ratio (95% CI).
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based psychological treatment in clinical services,49 and thus
a key efficacy question is whether SlowMo therapy confers ben-
efits beyond those of TAU. Garety et al9 previously estab-
lished the superiority of an earlier brief version of the inter-
vention against an active control intervention. Examination
of mechanisms of change also required a control condition as
much as possible inert with respect to reasoning. A further limi-
tation is that our primary outcome, the GPTS score, uses self-
report and was revised during the trial.31 However, the more
psychometrically robust revision31 yielded similar results but
with slightly larger effects. In addition, the use of blinded
observer-rated measures of delusions (yielding moderate ef-
fect sizes) was consistent with improvement in clinically se-
vere paranoia. Furthermore, we did not assess functioning;
however, we did measure quality of life36 and well-being,35 in-
dicating improvements in satisfaction with a range of do-
mains of everyday life and function.
Conclusions
This is the first randomized clinical trial, to our knowledge, to
test a blended digital therapy for paranoia in people with psy-
chosis. Although no effect was demonstrated on the primary
paranoia outcome at 24 weeks, the pattern of results on sec-
ondary outcomes indicates SlowMo had a positive effect on
paranoia, mostly sustained at follow-up, that matched or ex-
ceeded effects observed for standard CBTp albeit delivered
in fewer sessions.50 Improvements in well-being, quality of
life, and self-concept also occurred. The results indicate that
the treatment was effective, in part, through helping people
to slow down their thinking and to worry less. Further under-
standing of the mechanisms of action of SlowMo is war-
ranted. The trial results also indicate the need for future work
to enhance and translate the effects of SlowMo.
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